research use only
Cat.No.S4605
|
In vitro |
DMSO
: 2 mg/mL
(4.53 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 441.40 | Formula | C19H19N7O6 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 59-30-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Folacin, Vitamin B9, Vitamin M, Pteroylglutamic acid, Folate | SMILES | C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N | ||
Read more about storage stability stock solution CAS number SMILES
| In vitro |
Folic acid treatment induces dose-related increases in BRCA1 mRNA expression in HepG2, Huh-7D12, Hs578T, and JURKAT and in BRCA2 in HepG2, Hs578T, MCF7, and MDA-MB-157 cells. This compound does not affect the corresponding normal cells or on any of the ovarian cell lines. It induces increased BRCA1 protein expression in Hs578T, but not HepG2 cells, whereas BRCA2 protein levels are undetectable. FA treatment does not alter DNA repair in liver-derived cells, whereas there are transient effects on breast-derived cells. There is no effect of this treatment on BRCA1 or BRCA2 DNA methylation, although there is some variation in the methylation of specific CpG loci between some cell lines.
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2026-01-14)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07113158 | NOT_YET_RECRUITING | Sudden Sensorineural Hearing Loss |
Assistance Publique - Hôpitaux de Paris |
2026-04-01 | PHASE3 |
| NCT06641245 | NOT_YET_RECRUITING | Folate; Folate Bioavailability; Clinical Trials; Pregnancy |
University of British Columbia |
2025-01-31 | |
| NCT07241221 | RECRUITING | Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM) |
National University Hospital, Singapore |
2025-12 | |
| NCT07695883 | NOT_YET_RECRUITING | Neurodevelopment Outcome; Linear Growth; Micronutrient Status; Bone Mineral Density; Underweight; Stunting; Body Composition; Blood Pressure; HRQOL (Health Related Quality Of Life); Waist-to-height Ratio |
Johns Hopkins Bloomberg School of Public Health |
2026-10-01 | PHASE3 |
| NCT07697196 | NOT_YET_RECRUITING | HPV Infection; HPV Integration; HPV Disease; HPV Genital Infection; HPV Persistence; Low Grade Squamous Intraepithelial Lesions of the Cervix |
IRCCS San Raffaele |
2026-07 | |
| NCT07680595 | RECRUITING | Carotid Atherosclerotic Plaque |
Ruijin Hospital |
2026-03-01 | PHASE1; PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.